Sign In
Buy SMTI
Sanara Medtech Earnings Calls
| Release date | May 11, 2026 |
| EPS estimate | -$0.0400 |
| EPS actual | $0.0400 |
| EPS Surprise | 200.00% |
| Revenue estimate | 26.8M |
| Revenue actual | 27.799M |
| Revenue Surprise | 3.73% |
| Release date | Mar 24, 2026 |
| EPS estimate | $0.110 |
| EPS actual | $0.0400 |
| EPS Surprise | -63.64% |
| Revenue estimate | 27.4M |
| Revenue actual | 27.546M |
| Revenue Surprise | 0.532% |
| Release date | Nov 12, 2025 |
| EPS estimate | -$0.240 |
| EPS actual | $0.0900 |
| EPS Surprise | 137.50% |
| Revenue estimate | 27.2M |
| Revenue actual | 26.334M |
| Revenue Surprise | -3.18% |
| Release date | Aug 13, 2025 |
| EPS estimate | -$0.330 |
| EPS actual | -$0.230 |
| EPS Surprise | 30.30% |
| Revenue estimate | 26.6M |
| Revenue actual | 25.831M |
| Revenue Surprise | -2.89% |
Last 4 Quarters for Sanara Medtech
Below you can see how SMTI performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 13, 2025 |
| Price on release | $31.92 |
| EPS estimate | -$0.330 |
| EPS actual | -$0.230 |
| EPS surprise | 30.30% |
| Date | Price |
|---|---|
| Aug 07, 2025 | $24.36 |
| Aug 08, 2025 | $24.80 |
| Aug 11, 2025 | $26.86 |
| Aug 12, 2025 | $27.47 |
| Aug 13, 2025 | $31.92 |
| Aug 14, 2025 | $30.40 |
| Aug 15, 2025 | $29.68 |
| Aug 18, 2025 | $31.58 |
| Aug 19, 2025 | $30.86 |
| 4 days before | 31.03% |
| 4 days after | -3.32% |
| On release day | -4.76% |
| Change in period | 26.68% |
| Release date | Nov 12, 2025 |
| Price on release | $21.11 |
| EPS estimate | -$0.240 |
| EPS actual | $0.0900 |
| EPS surprise | 137.50% |
| Date | Price |
|---|---|
| Nov 06, 2025 | $27.87 |
| Nov 07, 2025 | $27.72 |
| Nov 10, 2025 | $28.16 |
| Nov 11, 2025 | $28.04 |
| Nov 12, 2025 | $21.11 |
| Nov 13, 2025 | $19.61 |
| Nov 14, 2025 | $21.54 |
| Nov 17, 2025 | $21.07 |
| Nov 18, 2025 | $20.90 |
| 4 days before | -24.26% |
| 4 days after | -0.99% |
| On release day | -7.11% |
| Change in period | -25.01% |
| Release date | Mar 24, 2026 |
| Price on release | $18.08 |
| EPS estimate | $0.110 |
| EPS actual | $0.0400 |
| EPS surprise | -63.64% |
| Date | Price |
|---|---|
| Mar 18, 2026 | $18.66 |
| Mar 19, 2026 | $18.72 |
| Mar 20, 2026 | $18.38 |
| Mar 23, 2026 | $18.34 |
| Mar 24, 2026 | $18.08 |
| Mar 25, 2026 | $16.34 |
| Mar 26, 2026 | $18.01 |
| Mar 27, 2026 | $16.96 |
| Mar 30, 2026 | $17.29 |
| 4 days before | -3.11% |
| 4 days after | -4.37% |
| On release day | -9.62% |
| Change in period | -7.34% |
| Release date | May 11, 2026 |
| Price on release | $18.02 |
| EPS estimate | -$0.0400 |
| EPS actual | $0.0400 |
| EPS surprise | 200.00% |
| Date | Price |
|---|---|
| May 05, 2026 | $19.62 |
| May 06, 2026 | $19.15 |
| May 07, 2026 | $19.08 |
| May 08, 2026 | $18.40 |
| May 11, 2026 | $18.02 |
| May 12, 2026 | $20.44 |
| May 13, 2026 | $21.10 |
| May 14, 2026 | $21.64 |
| May 15, 2026 | $21.06 |
| 4 days before | -8.15% |
| 4 days after | 16.87% |
| On release day | 13.43% |
| Change in period | 7.34% |
Sanara Medtech Earnings Call Transcript Summary of Q1 2026
Sanara MedTech reported a strong Q1 2026 that exceeded expectations: net revenue rose 19% year-over-year driven by soft tissue repair products (CellerateRX and BIASURGE), gross margin improved to ~93%, and the company reached GAAP net income from continuing operations of $0.4 million ($0.04 per diluted share). Adjusted EBITDA rose 58% to $4.3 million. The company is executing a strategic shift to be a pure-play surgical-focused business, expanded its salesforce to 43 reps, grew its distributor base to over 450 partners, and has product approvals/contracts in 4,000+ hospitals/ASCs with sales in ~1,400 facilities. Management reiterated full-year 2026 revenue guidance of $116M–$121M (≈13%–17% growth) and Q2 revenue guidance of $28.5M–$29.5M (10%–14% growth). Key pipeline and capital allocation items include continued R&D investment, a focus on next-gen products and IP, and the planned market introduction of OsStic (synthetic injectable bioadhesive bone-void filler) targeted for Q1 2027. Balance sheet: $13.6M cash and $46.2M long-term debt as of March 31, 2026; net cash used in operations was $2.5M for the quarter. Management highlighted an important operational milestone—paying debt service entirely in cash during the quarter—as evidence of improving free cash flow generation. Risks called out include general forward-looking uncertainties, seasonality (Q1 historically slow), and potential hospital budget pressures.
